High-dose rifampicin for 3 months after culture conversion for drug-susceptible pulmonary tuberculosis

This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacteriu...

Full description

Saved in:
Bibliographic Details
Published in:Tuberculosis and respiratory diseases 2025, 88(1), 401, pp.170-180
Main Authors: Kwak, Nakwon, Kim, Joong-Yub, Kim, Hyung-Jun, Kwon, Byoung-Soo, Lee, Jae Ho, Mok, Jeongha, Kwon, Yong-Soo, Kang, Young Ae, Park, Youngmok, Lee, Ji Yeon, Jeon, Doosoo, Lee, Jung-Kyu, Yang, Jeong Seong, Whang, Jake, Kim, Kyung Jong, Kim, Young Ran, Cheon, Minkyoung, Park, Jiwon, Hahn, Seokyung, Yim, Jae-Joon
Format: Article
Language:English
Subjects:
내과학
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at
ISSN:1738-3536
2005-6184
2005-6184
DOI:10.4046/trd.2024.0099